Evaluation of Addition of Reactive Resin for an Adhesive Formulation of Pressure-Sensitive Adhesive

Nowadays, adhesive industry is growing, and its development will be important in a short future because it offers good returns, and in some cases it is a better option for packaging and sealing with advantages in prices, productivity and weight reduction. In terms of joining and/or sealing, adhesives are well positioned among joining systems; however, knowledge about adhesives is need for their efficient use and only through proper design of the union can be achieved satisfactory results. In this chapter, a development of a formulation of pressure-sensitive adhesive based on styrene-butadiene copolymers using a reactive resin is reported. Non-aromatic solvents were used in adhesive formulation with the aim of avoiding the emission of harmful solvents into the Atmosphere, and the adequate combination and amount of solvents were found. The effect of addition of a phenolic resin in the adhesive formulation as a crosslinking agent was evaluated. By means Fourier Transform Infrared spectroscopy (FTIR), the crosslinking reaction was also studied. The performance of adhesive formulation was evaluated by means of dynamic mechanical analysis (DMA)

Case Report Myasthenia Gravis and Stroke in the Setting of Giant Cell Arteritis

This case report concerns the diagnosis of two independent chronic diseases in a patient hospitalized for stroke, myasthenia gravis (MG) and giant cell arteritis (GCA). MG has been found to be associated with several diseases, but there are very few cases documenting its coexistence with GCA. We report the case of a 79-year-old woman initially hospitalized for stroke. Patient's concurrent symptoms of blepharoptosis, dysphagia, and proximal muscle weakness were strongly suggestive of myasthenia gravis. The persistent low-grade fever and elevated inflammatory markers in combination with the visual deterioration that developed also raised the suspicion of GCA. Histological examination confirmed GCA, while muscle acetylcholine receptor antibodies were also present. Even though in medicine one strives to interpret a patient's symptoms with one diagnosis, when one entity cannot fully interpret the clinical and laboratory findings, clinicians must consider the possibility of a second coexisting illness

Deposition of Ibuprofen Crystals on Hydroxypropyl Cellulose/Polyacrylamide Gel: Experimental and Mathematic Modeling Releasing

The crystallization of nonsteroidal anti-inflammatory drug [2-(4-isobutyl-phenyl) propionic acid] ibuprofen (IBP) on a hydroxypropyl cellulose (HPC) and polyacrylamide (PAAm) gel was studied as well as the release kinetics of the drug. The IBP was crystallized on the gel surface of HPC/PAAm. It had a prismatic shape and the growth was made in an aqueous medium; the crystallinity grade of the gels HPC/PAAm and HPC/PAAm-IBU increased to 68% and to 58%, respectively. The release of IBP is performed by two means: by a non-Fickian diffusion process and by relaxation of the chains of the gel; without regard to temperature and the diffusion media, this correlates with the lower critical solution temperature (LCST) of the proposed gel. This polymer matrix provides an option for releasing nonsteroidal anti-inflammatory drugs in a temperature range of 35–39°C. Korsmeyer and Peppas mathematical model was simulated for data releases, statistically significant at 95% confidence level

Advances in physiopathology of rheumatoid arthritis: Time for a new theory? [Avances sobre la fisiopatogenia de la artritis reumatoide, ¿Tiempo para una nueva teoría?]

[No abstract available

Pharmacogenomics of methotrexate: Strategy for a more individualized therapy in patients with rheumatoid arthritis [Farmacogenómica del metotrexate: Estrategia para una terapéutica más individualizada en pacientes con artritis reumatoide]

Rheumatoid arthritis (RA) is a common rheumatic disease in Mexico. Methotrexate (MTX) is a drug frequently used in the treatment of this disease. However, treatment discontinuation due to side effects is also common. Inter-individual differences in effectiveness and occurrence of side effects in RA patients treated with MTX (RA-MTX) have been reported. Several studies analyzed the presence of MTHFR C677T and A1298C polymorphisms in RAMTX patients associated with effectiveness, side effects and toxicity. Given the high frequency of the MTHFR C677T polymorphism in Mexico, it is of utmost interest to determine the allelic and genotypic frequency of these polymorphisms in patients with RA-MTX. The use of molecular techniques, feasible in our country, such as PCR/ RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) can allow us to identify these MTHFR genotypes among RA-MTX patients in order to target patients at risk of developing drug toxicity, side effects or better MTX efficacy. The ultimate goal is to develop individualized treatment, as promised by the field of pharmacogenomics

Pharmacogenomics of methotrexate: Strategy for a more individualized therapy in patients with rheumatoid arthritis [Farmacogenómica del metotrexate: Estrategia para una terapéutica más individualizada en pacientes con artritis reumatoide]

Rheumatoid arthritis (RA) is a common rheumatic disease in Mexico. Methotrexate (MTX) is a drug frequently used in the treatment of this disease. However, treatment discontinuation due to side effects is also common. Inter-individual differences in effectiveness and occurrence of side effects in RA patients treated with MTX (RA-MTX) have been reported. Several studies analyzed the presence of MTHFR C677T and A1298C polymorphisms in RAMTX patients associated with effectiveness, side effects and toxicity. Given the high frequency of the MTHFR C677T polymorphism in Mexico, it is of utmost interest to determine the allelic and genotypic frequency of these polymorphisms in patients with RA-MTX. The use of molecular techniques, feasible in our country, such as PCR/ RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) can allow us to identify these MTHFR genotypes among RA-MTX patients in order to target patients at risk of developing drug toxicity, side effects or better MTX efficacy. The ultimate goal is to develop individualized treatment, as promised by the field of pharmacogenomics